ArticleBMC pulmonary medicine2025
Determination of the frequency of sarcopenia in patients admitted with COPD diagnosis with the SARC-F survey.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSarcopenia is recognized as a consequence of hormones, immune system changes, and chronic inflammatory diseases that occur with aging. For the diagnosis of sarcopenia, the European Working Group on Sarcopenia in Older People (EWGSOP2) criteria are used. Furthermore, the fat-free mass index (FFMI), a marker of sarcopenia, is used to predict sarcopenic patients. In patients with chronic obstructive pulmonary disease (COPD), systemic inflammation, advanced age, sedentary lifestyle, and poor nutrition may lead to sarcopenia. This study aimed to investigate the contribution of the SARC-F questionnaire, a simple questionnaire to rapidly diagnose sarcopenia, in the prediction of sarcopenic patients secondary to COPD.
methodOur study included patients aged 50 years and older who were diagnosed with COPD and who signed an informed consent form. Demographic data, symptoms, anthropometric measurements, pulmonary function tests, a 6-minute walk test, and blood parameters were evaluated. The SARC-F questionnaire was administered to the participants. In our study, the correlation of sarcopenic patients according to FFMI with the SARC-F questionnaire was analyzed. The significance value was accepted as p < 0.05 in the statistical analysis of the study's data.
resultsThe data from 130 participants were analyzed in the study. Of the patients, 99 (76.2%) were male, 31 (23.8%) were female, and the mean age was 68.0 ± 9.6 years. According to the SARC-F results, the number of patients with < 4 points was 103 and the number of patients with ≥ 4 points was 27. According to the FFMI, the number of patients without sarcopenia was 96 and the number of patients with sarcopenia was 34. A statistically significant correlation was found between the FFMI and the sarcopenia indicators assessed by the SARC-F (p < 0.001).
conclusionPatients' adaptation to a sedentary lifestyle, COPD exacerbations causing systemic inflammation, and advanced age increase the likelihood of sarcopenia. The advanced age of patients diagnosed with COPD normalizes the loss of muscle strength, which delays the early diagnosis and treatment of sarcopenia. This study emphasizes the importance and practical usefulness of the SARC-F questionnaire in achieving the goals of early diagnosis and treatment of sarcopenia in all COPD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.